Adverum Biotechnologies Interest Expense 2011-2026 | ADVM

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Adverum Biotechnologies

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
8.23 M	5.75 M	-	-	-	-	4.2 M	2.7 M	762 K	370 K	18 K	73 K	8 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
8.23 M	8 K	2.46 M

Quarterly Interest Expense Adverum Biotechnologies

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
371 K	664 K	-	2.09 M	2.41 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.15 M	1.22 M	-	1.26 M	1.09 M	746 K	-	742 K	663 K	489 K	-	206 K	222 K	116 K	-	117 K	116 K	52 K	-	18 K	4 K	14 K	-	28 K	20 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
2.41 M	4 K	600 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
I-Mab IMAB	722 K	-	-	$ 866 M	China
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Adagene ADAG	1.11 M	$ 2.6	-1.12 %	$ 146 M	China
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.51	-0.52 %	$ 8.45 B	Australia
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 4.21	1.2 %	$ 9.16 B	Israel
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	887 K	$ 1.49	7.19 %	$ 279 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Ascendis Pharma A/S ASND	65.5 M	$ 221.8	-0.16 %	$ 5 B	Danmark
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Athira Pharma ATHA	3.96 M	-	-	$ 269 M	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	9.29 M	$ 1.46	2.46 %	$ 373 M	Britain
Amneal Pharmaceuticals AMRX	11.8 M	$ 14.49	-0.24 %	$ 4.48 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aytu BioScience AYTU	-512 K	$ 2.35	-1.81 %	$ 14.8 M	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA